W.H.P.M.

W.H.P.M. develops and manufactures rapid diagnostic tests—primarily one-step membrane immunoassays—for medical diagnostics including fecal occult blood testing for colorectal cancer screening, COVID‑19 antigen detection, and multi-panel drug testing. The company has conducted large-scale clinical studies in China for its colorectal cancer screening products and supplies both branded and private label/OEM diagnostic devices globally. It also produces its own antibodies to ensure quality control across product lines. The company received an FDA warning letter in June 2022 related to labeling/export compliance on certain COVID‑19 test kits distributed in the U.S.